A Comparison of Acute and Long-term Toxicities in Bone Marrow Donors With and Without G-CSF Treatment Prior to Harvest: A Companion Study to ASCT0631

Inclusion Criteria

DISEASE CHARACTERISTICS:

- Appropriately HLA-matched (HLA, A, B, DRB1 identical or antigen mismatched [i.e., 5/6
or 6/6 antigens matched]) sibling of the bone marrow recipient enrolled on
COG-ASCT0631

- Adequate size relative to the recipient (i.e., harvesting the maximum of 20 cc/kg
from the donor would result in a bone marrow graft that will provide an adequate cell
and volume dose to the recipient, in the opinion of the treating physician)

- Enrolled on the COG Umbrella Long-Term Follow-Up Study COG-ALTE05N1

PATIENT CHARACTERISTICS:

- Not pregnant or nursing

- No HIV positivity

- No sickle cell trait or sickle cell anemia/disease

- Not at an increased risk from bone marrow donation after filgrastim administration
due to a pre-existing medical condition, as determined by an independent physician
separate from the research team

- None of the following:

- Active infection, especially pulmonary

- Splenomegaly or a history of splenic injury

- Active or recent pulmonary disease (i.e., pneumonia within the past 4 weeks)

- A condition that would make the donor unsuitable to donate, as determined by an
independent physician separate from the research team

- No autoimmune disease

PRIOR CONCURRENT THERAPY:

- Not specified